Results 221 to 230 of about 60,638 (288)

Platelet activating factor (PAF) and lyso-PAF in psoriasis

Archives of Dermatological Research, 1994
Previous studies have shown that scale from lesional psoriatic skin contains substantial amounts of platelet activating factor (PAF). In this study, PAF and its immediate precursor, lyso-PAF, were measured in exudates from abrasions on lesional and uninvolved psoriatic skin, and from skin of healthy subjects.
M R, Judge, R M, Barr, A I, Mallet, F, Courtney, A, Kobza Black, M W, Greaves   +5 more
openaire   +2 more sources

PAF Receptor And “Cache-Oreilles” Effect. Simple PAF Antagonists

Lipids, 1991
AbstractNine simple and structurally flexible PAF antagonists were synthesized and their inhibitory effects on PAF induced platelet aggregation were measured. Compounds with PAF antagonistic activity exhibited a negative electrostatic potential generated by two trimethoxyphenyl groups (isocontour at −10 Kcal/mole) at various distances between the ...
J, Lamotte-Brasseur, F, Heymans, G, Dive, A, Lamouri, J P, Batt, C, Redeuilh, D, Hosford, P, Braquet, J J, Godfroid   +8 more
openaire   +2 more sources

PAF Receptor Structure

Lipids, 1991
AbstractDifferent hypotheses of the structure of platelet‐activating factor (PAF) receptor based on structure‐activity relationships of agonists and antagonists are reviewed. For an agonistic effect, strong hydrophobic interactions and an ether function are required in position‐1 of the glycerol backbone; chain length limitations and steric hindrance ...
J J, Godfroid, G, Dive, J, Lamotte-Brasseur, J P, Batt, F, Heymans   +4 more
openaire   +2 more sources

PAF responsiveness in Japanese subjects with plasma PAF acetylhydrolase deficiency

Biochemical and Biophysical Research Communications, 2004
Approximately 4% of the Japanese population genetically lack plasma platelet activating factor acetylhydrolase (PAF-AH) and show a higher prevalence of thromboembolic disease, but whether they are susceptible to another PAF-related disease, asthma, remains controversial.
Katsuhiko, Naoki, Koichiro, Asano, Nagato, Satoh, Kouichi, Fukunaga, Tsuyoshi, Oguma, Tetsuya, Shiomi, Yusuke, Suzuki, Takeshi, Nakajima, Kyoko, Niimi, Yoshiki, Shiraishi, Akitoshi, Ishizaka, Kazuhiro, Yamaguchi   +11 more
openaire   +2 more sources

Effects of a Novel PAF Antagonist, E6123, on PAF-Induced Biological Responses

European Journal of Pharmacology, 1990
E6123 is a new member of the benzodiazepine class of PAF antagonists. Although it has similar activity in vitro to the two representative antagonists WEB2347 and Y24180, in vivo it is far more active than these compounds. Thus E6123 was effective in inhibiting dose-dependently PAF-induced bronchoconstriction when administered orally or intravenously ...
H. Tsunoda, Y. Sakuma, K. Harada, K. Muramoto, S. Katayama, T. Horie, N. Shimomura, R. Clark, S. Miyazawa, K. Okano, Y. Machida, K. Katayama, I. Yamastu   +12 more
openaire   +2 more sources

Implication of PAF and Acetylhydrolase (PAF-AH) Activity in Periodontal Disease

1996
Platelet-activating factor (PAF) is a bioactive phospholipid produced by activated inflammatory cells such as polymorphonuclear leukocytes, macrophages, platelets and endothelial cells1. Previous research showed that PAF in vivo, increases vascular permeability and infiltration of PMNs 2.
G, Baltas, H, Kotsifaki, S, Antonopoulou, A, Kipioti, C A, Demopoulos   +4 more
openaire   +2 more sources

Paf‐acether in human skin

Lipids, 1991
AbstractPaf is a phospholipid mediator present in human skin which induces inflammatory events such as neutrophil infiltration and increased vascular permeability. Recent data suggest that cutaneous cells, such as fibroblasts and keratinocytes, produce paf and that paf is released during allergic cutaneous reactions.
Y, Denizot, L, Michel, J, Benveniste, A, Meybeck, Y, Thomas, L, Dubertret   +5 more
openaire   +2 more sources

Hypoxia, PAF, and Necrotizing Enterocolitis

Lipids, 1991
AbstractNecrotizing enterocolitis (NEC) is an important neonatal disease with a high mortality rate. The pathophysiology is unclear but epidemiologic studies suggest that hypoxia and infection are important risk factors. In this review we discuss the effect of hypoxia and platelet‐activating factor (PAF) on intestinal blood flow and intestinal necrosis,
M S, Caplan, X M, Sun, W, Hsueh
openaire   +2 more sources

Structure of complete Pol II–DSIF–PAF–SPT6 transcription complex reveals RTF1 allosteric activation

Nature Structural & Molecular Biology, 2020
S. Vos, L. Farnung, A. Linden, H. Urlaub, P. Cramer   +4 more
semanticscholar   +1 more source

Platelet-activating factor (PAF) and PAF antagonists in asthma.

Critical reviews in therapeutic drug carrier systems, 1991
PAF is produced by and activates inflammatory cells, such as monocytes/macrophages, mast cells, platelets, neutrophils, eosinophils and endothelial cells. Its ability to imitate anaphylaxis, inducing for instance bronchoconstriction (BC) in guinea-pigs, and its identification (and/or that of lyso-PAF) in exudates from shocked lungs, led to the ...
D, Hosford, J M, Mencia-Huerta, P, Braquet   +2 more
openaire   +1 more source